Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?

Key Takeaways AbbVie's neuroscience segment generated $10.8B in 2025 revenue, rising nearly 20% year over year.ABBV saw double-digit growth from Botox Therapeutic, Vraylar, Qulipta and Ubrelvy, with Vyalev adding $482M.ABBV expects $12.5B neuroscience sales in 2026 and aims for Vyalev to surpass $1B in global revenues.AbbVie (ABBV) reported encouraging fourth-quarter and full-year 2025 results last month. While the company’s immunology portfolio accounted for the bulk of revenue growth, its neuroscience fra ...